| Symbol | NUVL |
|---|---|
| Name | NUVALENT, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | ONE BROADWAY,14TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 857 - 357-7000 |
| Fax | — |
| — | |
| Website | https://www.nuvalent.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001861560 |
| Description | Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Additional info from NASDAQ: |
2026-06-11 20:30
Noci Darlene 🟡 adjusted position in 20.0K shares (3 derivative) of Nuvalent, Inc. (NUVL) at $122.81 ($2.8M) Transaction Date: Jun 09, 2026 | Filing ID: 000007
Read more
2026-06-10 17:54
New Form SC TO-C - Nuvalent, Inc. <b>Filed:</b> 2026-06-10 <b>AccNo:</b> 0001193125-26-265991 <b>Size:</b> 649 KB
Read more
2026-06-10 15:19
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Read more
2026-06-10 14:45
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders
Read more
2026-06-09 20:04
📋 Darlene Noci (Officer) plans to sell 48K shares of Nuvalent, Inc. (at $122.81 each, total $6.0M) Filed: Jun 09, 2026 | ID: 000569
Read more
2026-06-09 18:21
New Form SC TO-C - Nuvalent, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001193125-26-264048 <b>Size:</b> 10 MB
Read more
2026-06-09 18:19
New Form SC14D9C - Nuvalent, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001193125-26-264042 <b>Size:</b> 137 KB
Read more
2026-06-09 13:05
NUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders
Read more
2026-06-09 08:14
New Form SC TO-C - Nuvalent, Inc. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001193125-26-262957 <b>Size:</b> 73 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06834074 | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+… | — | Non Small Cell Lung Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced RO… | — | Non Small Cell Lung Cancer | Available | — | — | ClinicalTrials.gov |
| NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase3 | Non-small Cell Lung Cancer | Recruiting | 2025-07-17 | 2029-12-01 | ClinicalTrials.gov |
| NCT06521554 | A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (… | Phase1 | Locally Advanced Solid Tumor | Recruiting | 2024-07-18 | 2027-02-01 | ClinicalTrials.gov |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid… | Phase1 | Locally Advanced Solid Tumor | Recruiting | 2022-06-09 | 2028-01-01 | ClinicalTrials.gov |
| NCT05118789 | A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Sol… | Phase1 | Locally Advanced Solid Tumor | Recruiting | 2022-01-04 | 2028-12-31 | ClinicalTrials.gov |
Total clinical trials: 6
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NVL-520 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06797362 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-520 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06797362 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Itraconazole | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Repaglinide | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Midazolam | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05384626 |
| Zidesamtinib (NVL-520) | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05118789 |
| NVL-520 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06797362 |
| NVL-330 | Other | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT06521554 |
| Alectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Neladalkib (NVL-655) | Other | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-655 | Other | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-655 | DRUG | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06834074 |
| NVL-520 | DRUG | Preclinical | Non Small Cell Lung Cancer | AVAILABLE | NCT06797362 |
| Alectinib | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| NVL-330 | DRUG | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT06521554 |
| Neladalkib (NVL-655) | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer | RECRUITING | NCT06765109 |
| Zidesamtinib (NVL-520) | DRUG | Phase PHASE1 | Locally Advanced Solid Tumor | RECRUITING | NCT05118789 |
Total products: 105